Early administration of tofacitinib in COVID-19 pneumonitis: An open randomised controlled trial.
Alessia FerrariniAngelo VaccaAntonio Giovanni SolimandoMarcello TavioRossella AcquavivaMarco RocchiCinzia NittiAldo SalviVincenzo MendittoMichele Maria Luchetti GentiloniAlessandro RussoMarco MorettiMarianna PavaniAndrea GiacomettiMartina BonifaziLina ZuccatostaLaura RomaniGianluca MoronciniArmando GabrielliGiovanni PomponioPublished in: European journal of clinical investigation (2022)
High-dose tofacitinib therapy in patients with COVID pneumonitis is safe and may prevent deterioration to respiratory failure.
Keyphrases
- respiratory failure
- high dose
- rheumatoid arthritis
- interstitial lung disease
- extracorporeal membrane oxygenation
- coronavirus disease
- ulcerative colitis
- mechanical ventilation
- sars cov
- study protocol
- low dose
- stem cell transplantation
- acute respiratory distress syndrome
- systemic sclerosis
- randomized controlled trial
- respiratory syndrome coronavirus
- cell therapy
- smoking cessation
- replacement therapy